DDInter94 DDInter542
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mechlorethamine
Mechlorethamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) VKORC1
VKORC1 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Mercaptopurine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) upregulates {v} (Gene) CRYZ
CRYZ {u} (Gene) is bound by {v} (Compound) Dicoumarol
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) downregulates VKORC1 (Gene) and VKORC1 (Gene) is bound by Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) upregulates CRYZ (Gene) and CRYZ (Gene) is bound by Dicoumarol (Compound)